ACADIA Pharmaceuticals Inc (NAS:ACAD)
$ 16.32 0.37 (2.32%) Market Cap: 2.71 Bil Enterprise Value: 2.20 Bil PE Ratio: 90.67 PB Ratio: 5.23 GF Score: 74/100

ACADIA Pharmaceuticals Inc Announces Positive Top-line Results Call Transcript

Dec 06, 2021 / 09:30PM GMT
Release Date Price: $19.4 (+3.25%)
Operator

Good day, ladies and gentlemen, and welcome to ACADIA Pharmaceuticals conference call. My name is Towanda, and I will be your coordinator for today. (Operator Instructions)

I would now like to turn the presentation over to Mark Johnson, Vice President of Investor Relations of ACADIA. You may proceed.

Mark C. Johnson
ACADIA Pharmaceuticals Inc. - VP of IR

Thank you, Towanda. Good afternoon, and thank you for joining us on today's call to discuss the positive top line results from the pivotal Phase III LAVENDER study evaluating trofinetide as a potential treatment for Rett syndrome. On today's call, Steve Davis, our CEO; and Serge Stankovic, our President, will provide some opening remarks. Following Serge, we will hear from Dr. Dominique Pichard, Chief Scientific Officer at the International Rett Syndrome Foundation, who will discuss Rett syndrome and the unmet need in greater detail. Then Kathie Bishop, our Chief Scientific Officer and Head of Rare Disease, will walk us through the LAVENDER results. Finally, Steve Davis will provide some closing

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot